Objective: To clarify the expression of MAP4K4 in gastric carcinoma and its relationship with clinical pathological features of gastric carcinoma and further reveal the role of MAP4K4 in the development of gastric cancer.
Methods: We randomly selected 20 patients diagnosed with GC by clinical signs and symptoms, imaging diagnosis and laboratory diagnosis in department of general surgery in University Medical department Affiliated Hospital from January 2014 to December 2015. Gastric cancer tissues and adjacent tissues were studied with immuno histochemistry staining and the expression level of MAP4K4 level was detected postoperatively. The relationship between the MAP4K4 expression level and the clinical stage, pathological grade relationship was analysed. The Kaplan-Meier method was used to analyse the effect of MAP4K4 expression level on clinical outcome.
Result: The expression level of MAP4K4 gene was related to lymph node metastasis and pathological staging of gastric cancer (P<0.05), but it was not related to the tumor size and recurrence and metastasis of gastric cancer (P>0.05). In the -~+ group, the median progression free survival was (4.98 ± 14.42) months; the median progression of free survival was (34.00 ± 27.56) months. In ++~+++ group, the median progression free survival was (19.57 ± 4.76) months, and the median progression free survival was (13.00 ± 1.25) months. The difference was statistically significant (2=13.167; P=0.005). In-~+ group, the average survival time was (65 ± 116.70) months, the median overall survival was (50 ± 39.90) months. The difference was statistically significant (2=10.084; P=0.003). Conclusion: The expression level of MAP4K4 in gastric cancer patients was significantly increased, and it was negatively correlated with the pathological grade of gastric cancer.